Navigation Links
Meningoencephalitis Panel, CSF with Reflex to HSV Type 1 & Type 2 Glycoprotein G-Specific Ab, IgG

ProductsMeningoencephalitis Panel, CSF with Reflex to HSV Type 1 & Type 2 Glycoprotein G-Specific Ab, IgG
Company ARUP Laboratories
Item Meningoencephalitis Panel, CSF with Reflex to HSV Type 1 & Type 2 Glycoprotein G-Specific Ab, IgG
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Meningoencephalitis Panel, Serum with Reflex to HSV Type 1 & Type 2 Glycoprotein G-Specific Ab, IgG
2. ANCA Panel, IgG
3. Anti-Neutrophil Cytoplasmic Antibodies Panel, IgG
4. Antidepressant Panel, Urine
5. Antigen & Mitogen Proliferation Panel, Lymphocytes
6. Borrelia hermsii Antibody Panel, IFA
7. Chlamydia Antibody Panel, IgG by IFA
8. Chlamydia Antibody Panel, IgM by IFA
9. Chlamydia Antibody Panel, IgG & IgM by IFA
10. Coccidioides Antibodies Panel, CSF by CF, ID, ELISA
11. Coccidioides Antibodies Panel, Serum by CF, ID, ELISA
3.5v Coaxial Ophthalmoscope Set with Convertible Handle and Hard Case. Our 3.5v Coaxial Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
High-quality eyecare from the preferred name in diagnostic instruments....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products:
(Date:7/27/2015)... ... 27, 2015 , ... BESLER Consulting today announced the publication ... for Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP ... as the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Gary ... Jersey. Dr. Breslow is Founder and Medical Director of The Breslow Center in ... the face, breast, and body in Northern New Jersey. The Breslow Center also ...
(Date:7/27/2015)... ... 27, 2015 , ... For a limited time, Huntington Beach dentist , ... is a great time to change up a look or to simply brighten a ... affect your self-esteem. Over time, the enamel coating can become worn and can expose ...
(Date:7/27/2015)... ... 2015 , ... According to an article published by the Times Free ... Tennessee stemming from intravenous drug use. Intravenous drug use causes more overdoses and is ... diseases including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have ...
(Date:7/27/2015)... ... July 27, 2015 , ... Hexagon ... new way to understand and share your geospatial experience. These new light-weight applications ... to solve distinct business problems. , “Our world is more dynamic than it ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Doc, Dr. Gary Breslow, has launched Zwivel; a New Online Cosmetic Consultation Service for Doctors and Patients 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 2Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 3
... disease, experts say, , , THURSDAY, May 21 (HealthDay ... levels also reduce their risk of heart attack ... have been several conflicting reports about the value ... patients in preventing heart attack and heart disease. ...
... Bayer HealthCare Pharmaceuticals, Inc. today announced that ... 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual ... in Orlando, Florida, May 29 - June 2. ... the oral multi-kinase inhibitor BAY 73-4506 is one of ...
... Omnicare, Inc., which calls itself "the nation,s leading ... to settle Medicaid fraud charges by the State ... had committed Medicaid fraud by illegally switching the ... other facilities. Omnicare,s conduct had originally been ...
... New Method for Optimizing Cardiac Resynchronization Therapy During Exercise. The ... difference in treating CRT patients." Dr. Abraham Kocheril, Professor of ... Illinois at Chicago. , ... Minneapolis-St. ...
... A protein that plays a key role in tumor formation, ... that extends lifespan by dietary restriction. The finding, which appears ... PLoS Genetics , provides a new understanding of how ... scientists new targets for developing and testing drugs that could ...
... and lifestyle characteristics can be linked to different invasive ... presented in the open access journal Breast Cancer ... of the condition are associated with different kinds of ... Research, California, led a team of researchers who used ...
Cached Medicine News:Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 2Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 2Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 4Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 5Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 2Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 3Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 4Health News:Key protein may explain the anti-aging and anti-cancer benefits of dietary restriction 2
(Date:7/27/2015)... Calif. , July 27, 2015 Allergan ... (NASDAQ: KYTH ) today announced that the U.S. ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... acquisition of KYTHERA.  Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO ... of Allergan and KYTHERA filed a Pre-Merger Notification and ...
(Date:7/27/2015)... 2015   Mallinckrodt plc (NYSE: ... today that it has entered into a definitive ... contrast media and delivery systems (CMDS) business to ... at approximately $270 million.   Mallinckrodt,s ... with the company,s stated plan to strategically streamline ...
(Date:7/27/2015)... -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a ... the Company,s lead pharmaceutical product. EnzymeBioSystems plans to seek ... prevention of breast cancer. "We are pleased ... has been completed," stated Gary Rojewski , CEO ... will allow us to move forward in beginning to ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Amooranin Preclinical Sample Batch Completed 2